Showing results (81-90 of 211) with videos related to

Sort By:
Pageof 22
Biomedicines|November 27, 2021
Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic TreatmentsFederica Li Pomi, Laura Macca, Alfonso Motolese, et al.
Frontiers in Endocrinology|November 29, 2023
Surgical treatment of tertiary hyperparathyroidism: does one fit for all?Claudio Casella, Claudio Guarneri, Manuela Campanile, et al.
The Journal of Dermatological Treatment|September 25, 2018
Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experienceSerafinella P Cannavò, Elisa Postorino, Emanuela Aragona, et al.
Frontiers in Pharmacology|April 22, 2022
Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical TrialsVito Di Lernia, Laura Macca, Lucia Peterle, et al.
Mayo Clinic Proceedings|September 10, 2015
Fingolimod-Associated Peripheral Vascular Adverse EffectsMargherita Russo, Claudio Guarneri, Emanuela Mazzon, et al.
Frontiers in Medicine|July 24, 2023
Hidradenitis suppurativa and psoriasis: the odd coupleLaura Macca, Federica Li Pomi, Ylenia Ingrasciotta, et al.
Photodiagnosis and Photodynamic Therapy|May 29, 2020
Efficacy and safety of conventional versus daylight photodynamic therapy in children affected by multiple facial flat wartsFrancesco Borgia, Roberta Giuffrida, Marialorena Coppola, et al.
Italian Journal of Dermatology and Venereology|March 20, 2023
Dietary habits of psoriatic patients treated with dimethyl fumarate and drug-related side effects: results from an observational studyAlessandro Borghi, Giulia Odorici, Alberto Monti, et al.
Dermatology and Therapy|January 23, 2025
Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational StudyGiovanni Damiani, Alessia Pacifico, Stefano Ricciardi, et al.
Expert Opinion on Biological Therapy|March 6, 2024
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burdenPaolo Dapavo, Martina Burlando, Claudio Guarneri, et al.
Pageof 22